You just read:

Palatin Technologies Announces Completion of All Patient Visits In Phase 3 Clinical Trials of Bremelanotide for Hypoactive Sexual Desire Disorder

News provided by

Palatin Technologies, Inc.

04 Aug, 2016, 07:30 ET